BOUNDLESS BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.99 USD | +3.48% |
|
+18.43% | 0.00% |
| Apr. 22 | Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target | MT |
| Apr. 22 | Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 244.6 | - | - |
| Enterprise Value (EV) 1 | 213.8 | 208.3 | 143.4 |
| P/E ratio | -3.28 x | -2.95 x | -2.83 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -2.94 x | -1.91 x | -0.92 x |
| EV / FCF | -3.96 x | -2.98 x | -1.61 x |
| FCF Yield | -25.3% | -33.6% | -62.1% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 22,253 | - | - |
| Reference price 2 | 10.99 | 10.99 | 10.99 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA 1 | - | -72.68 | -109 | -156.4 |
| EBIT 1 | - | -73.72 | -99.89 | -126.8 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -71.95 | -93.82 | -110.6 |
| Net income 1 | -49.43 | -68.13 | -94.64 | -123.5 |
| Net margin | - | - | - | - |
| EPS 2 | -2.080 | -3.353 | -3.720 | -3.890 |
| Free Cash Flow 1 | - | -54 | -70 | -89 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Announcement Date | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -16.88 | -17.25 | -18.9 | -19.91 | -22.3 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -15.43 | -17.45 | -18.7 | -19.55 | -21.1 |
| Net income 1 | -15.43 | -16.87 | -18.03 | -18.8 | -21.1 |
| Net margin | - | - | - | - | - |
| EPS 2 | -12.27 | -0.7333 | -0.7733 | -0.7967 | -0.8900 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 5/13/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 30.7 | 36.3 | 101 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -54 | -70 | -89 |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 0.4 | 0.5 | 0.5 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/6/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10.99
USD
Average target price
23
USD
Spread / Average Target
+109.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 245M | |
| +8.63% | 114B | |
| +13.17% | 107B | |
| -12.76% | 22.22B | |
| -2.33% | 21.28B | |
| -4.97% | 18.8B | |
| -7.19% | 17.51B | |
| -39.93% | 17.17B | |
| +6.67% | 14.14B | |
| +33.90% | 12.2B |
- Stock Market
- Equities
- BOLD Stock
- Financials Boundless Bio, Inc.
